Skip to main content
SpringerLink
Log in

Interventionelle Hypertonietherapie

Renale Denervation zur Behandlung des Hochdrucks: noch lebensfähig?

  • Fortbildung
  • Schwerpunkt Hypertonie
  • Published:
CardioVasc Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Esler MD et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903-9

  2. Rosa J et al. Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension: Six-Month Results From the Prague-15 Study. Hypertension. 2015;65(2):407-13

  3. Fadl Elmula FEM et al. Adjusted Drug Treatment Is Superior to Renal Sympathetic Denervation in Patients With True Treatment-Resistant Hypertension. Hypertension. 2014;63(5):991-9

  4. Kario K et al. SYMPLICITY HTN-Japan - First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients. Circ J. 2015;79(6):1222-9

  5. Azizi M et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957-65

  6. Bakris GL et al. Impact of Renal Denervation on 24-Hour Ambulatory Blood PressureResults From SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64(11):1071-8

  7. Kandzari DE et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219-27

  8. Mathiassen ON et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens. 2016;34(8):1639-47

  9. Desch S et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension. 2015;65(6):1202-8

  10. Bohm M et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444-51

  11. Azizi M et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335-45

  12. Weber MA et al. The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension. JACC Cardiovasc Interv. 2020;13(4):461-70

  13. Kandzari DE et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346-55

Download references

Author information

Authors and Affiliations

  1. Charité - Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Deutschland

    Markus van der Giet

Authors
  1. Markus van der Giet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus van der Giet.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van der Giet, M. Renale Denervation zur Behandlung des Hochdrucks: noch lebensfähig?. CV 21, 42–44 (2021). https://doi.org/10.1007/s15027-020-3448-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-020-3448-2

Search

Navigation